Harry Berkowitz, MD
Internal Medicine · Brooklyn, NYNPI 1164436515
Payments from drug & device makers
Across 96 payments — averaging $73.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Lilly USA, LLC$899
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$280
- Novo Nordisk$278
- Boehringer Ingelheim$278
- Intuity Medical Inc$232
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $3,656 |
| Lilly USA, LLC | 28 | $899 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $280 |
| Novo Nordisk | 10 | $278 |
| Boehringer Ingelheim | 3 | $278 |
| Intuity Medical Inc | 3 | $232 |
| Corcept Therapeutics | 3 | $173 |
| Intra-sana Laboratories | 3 | $172 |
| Otsuka America Pharmaceutical, Inc. | 1 | $150 |
| Pharmacosmos Therapeutics Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $105 |
| AbbVie(2 entities) | 5 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
| Amarin Pharma, Inc. | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Merck | 4 | $60 |
| Amgen | 3 | $58 |
| GSK | 2 | $47 |
| Shield Therapeutics Inc | 2 | $46 |
| Aimmune Therapeutics, Inc. | 1 | $39 |
| Novartis | 2 | $38 |
| Gilead | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$500
- CAPLYTA$280
- MOUNJARO$250
- GLYCATE$163
- Reltone 400 Mg$163
- Reltone 200 Mg$163
- REXULTI$150
- Pogo Automatic Blood Glucose Monitoring System$136
- Ozempic$125
- Monoferric$125
- Korlym$125
How this compares
$7,092 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $137,860 |
| JardianceEmpagliflozin | 49 | $51,583 |
| JanuviaSitagliptin Phosphate | 61 | $51,546 |
| OzempicSemaglutide | 51 | $48,886 |
| TrulicityDulaglutide | 29 | $42,938 |
| EntrestoSacubitril/Valsartan | 24 | $22,965 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $21,360 |
| RexultiBrexpiprazole | 14 | $19,326 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,129 |
| MounjaroTirzepatide | 13 | $14,914 |
| TradjentaLinagliptin | 16 | $14,481 |
| FarxigaDapagliflozin Propanediol | 15 | $11,732 |
| InvokanaCanagliflozin | 12 | $7,886 |
| MyrbetriqMirabegron | 18 | $7,218 |
| LinzessLinaclotide | 12 | $7,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $278 | $72,94678 claims |
| MerckJanuvia, Janumet | $60 | $72,90683 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $899 | $57,85242 claims |
| Novo NordiskOzempic | $278 | $48,88651 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $47 | $30,10450 claims |
| NovartisEntresto | $38 | $22,96524 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $150 | $19,32614 claims |
| AstraZenecaFarxiga, Symbicort | $3,656 | $14,59329 claims |
| AbbVieLinzess, Synthroid | $93 | $8,70141 claims |
| Johnson & JohnsonInvokana | $12 | $7,88612 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $7,21818 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $14 | $6,20516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.